Trial Profile
An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects greater than or Equal to 1 and Less Than or Equal to 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2023
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Cyclophosphamide; Cytarabine; Doxorubicin; Mercaptopurine; Methotrexate; Pegaspargase; Prednisone; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms DELPHINUS
- Sponsors Janssen Research & Development; Janssen-Cilag
- 21 Dec 2022 Status changed from active, no longer recruiting to completed.
- 14 Oct 2022 This trial has been completed in France (End Date: 22 Sept 2022), according to European Clinical Trials Database record
- 13 Oct 2022 Planned number of patients changed from 32 to 69.